Drug Topics

JULY 25, 2023

Radiation therapy was associated with the largest increase, compared to chemotherapy or endocrine therapies.

Chemotherapy 187

Chemotherapy 187

Pharmacy Times

JULY 25, 2023

Patients with type 2 diabetes receiving once-weekly insulin icodec were more likely to reach a hemoglobin A1C level below 7% compared to those who received once-daily insulin analogues.

123

123

Drug Topics

JULY 25, 2023

The report references adult vaccines, in terms of volume of use, for influenza, diphtheria and tetanus (Td), diphtheria, tetanus and pertussis (TDaP), hepatitis B, herpes zoster and pneumococcal.

Vaccines 98

Vaccines 98

Pharmacy Times

JULY 25, 2023

Co-developers Incyte and Syndax will submit a biologics license application to the FDA at the end of 2023 based on the results of a phase 2 trial among adult and pediatric patients with chronic graft-versus-host disease.

FDA 123

FDA 123

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

Fierce Healthcare

JULY 25, 2023

Two Cigna members have hit the insurer with a class action lawsuit, accusing the company of using an algorithm to improperly deny scores of patient claims. | Two Cigna members have hit the insurer with a class action lawsuit, accusing the company of using an algorithm to improperly deny scores of patient claims.

Insurance 98

Insurance 98

Pharmacy Times

JULY 25, 2023

The study authors said that further investigation is needed to explore specialized care for mothers and newborns who are affected by hepatitis C infections during pregnancy.

121

121

Pharmacy Times

JULY 25, 2023

The prolonged lack of viral exposure has likely increased the pool of children and adults vulnerable to respiratory syncytial virus, but questions remain.

123

123

STAT

JULY 25, 2023

Everyone knows that the United States is the only high-income country without universal health insurance. According to the standard narrative, this is the inevitable result of U.S. exceptionalism — our different values, culture, and institutions. Not so. The impetus for universal coverage is as strong in the United States as in any other country.

Insurance 98

Insurance 98

Pharmacy Times

JULY 25, 2023

Further work is necessary to monitor and develop understanding of recovery for individuals with ongoing COVID-19 symptoms.

120

120

STAT

JULY 25, 2023

With the advent of disease-modifying Alzheimer’s drugs, everyone in the world of Alzheimer’s diagnostics is bracing for the crush. Based on their ability to slow cognitive decline, the Eisai/Biogen drug Leqembi won full approval from the FDA this month, and donanemab by Eli Lilly could be approved by year end. Clinicians now have to decide which patients are most suitable for treatment, which means better Alzheimer’s tests need to be developed.

FDA 98

FDA 98

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

NF2 BioSolutions

JULY 25, 2023

It’s NF2 science, but summarised! The previous blog posts in this series: Science Summarised: Potential New Drugs for Hearing Loss Science Summarised: All Things Meningioma This blog was written by NF2 BioSolutions PhD student Grace Gregory. [Image Description] Grace Gregory in the laboratory at the University of Manchester. — Exciting news!

Immunization 98

Immunization Communication 98

Fierce Pharma

JULY 25, 2023

In reporting its first-quarter earnings, Biogen said it would halt the development of at least four investigational drugs to allow the company to focus on more lucrative opportunities. | In a sizable cost-cutting measure, Biogen will lay off 1,000 employees by 2025, it announced in presenting its second quarter earnings. With the company starting 2023 with 8,725 employees, that’s an 11.5% reduction of the workforce.

98

98

Fierce Healthcare

JULY 25, 2023

Hospitals are finding it harder to place patients into post-acute care settings, a new report finds. | The number of referrals to nursing homes and home health agencies per patient has increased over the last year, as has patient acuity. At the same time, referral rejection rates are also on the rise.

Nursing Homes 98

Nursing Homes Hospitals 98

Fierce Pharma

JULY 25, 2023

Patients with the eyelid disease Demodex blepharitis can now see a cure in Tarsus Pharmaceuticals’ Xdemvy, the first FDA-approved treatment for an ailment that affects some 25 million Americans.

FDA 98

FDA 98

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

STAT

JULY 25, 2023

Biogen announced a new round of cost cuts Tuesday, saying that it plans to save $700 million in operating costs and cut 1,000 jobs by 2025. The company also released second quarter sales and earnings that handily topped the forecasts of Wall Street analysts. In early morning trading, Biogen shares rose more than 1%. Biogen is attempting to recover from a series of corporate stumbles, the biggest of which involved the development and launch of the Alzheimer’s drug Aduhelm.

98

98

Fierce Pharma

JULY 25, 2023

Just as the calls for a business separation grow louder at Bayer, the company’s weedkiller performance is bolstering the argument with dramatically declining sales. | Just as the calls for a business separation grow louder at Bayer, the company’s weedkiller performance is bolstering the argument with dramatically declining sales.

98

98

STAT

JULY 25, 2023

SAN DIEGO — Truvian Health, a San Diego blood diagnostics company, shared data on Tuesday showing that its benchtop instrument’s results are largely consistent with those generated by large central laboratories. But while the results lend support for the company’s vision of decentralized and widely available clinical testing, they also resurface questions about the value of an approach widely associated with the now defunct and notorious Bay Area startup Theranos.

98

98

Fierce Healthcare

JULY 25, 2023

As demand surges for GLP-1 therapies, insurers are pulling back on coverage, according to new data from obesity care provider Found. | Sarah Jones Simmer, CEO of Found, said that the trends are likely the result of irresponsible prescribing for recreational reasons causing the pendulum to swing "all the way in the other direction," and it's leading to patients who have genuine medical need struggling to access these therapies.

Insurance 98

Insurance 98

STAT

JULY 25, 2023

Much has been made of Jesse Ehrenfeld’s career of firsts. The current president of the American Medical Association, inaugurated in June , has long advocated for safe and equitable care for sexual and gender minorities, leading to an inaugural National Institutes of Health award for his research in the area. The anesthesiologist was the youngest-ever officer of the Massachusetts Medical Society, and this year became the first openly gay president of the AMA.

98

98

Pharma Marketing Network

JULY 25, 2023

In today’s digital world, partnering with a competent and reliable digital marketing agency is crucial for businesses seeking to enhance their online presence, reach their target audience, and achieve their marketing goals. However, with countless agencies available, it can be overwhelming to find the right one that aligns with your business objectives.

Communication 98

Communication 98

STAT

JULY 25, 2023

A hearing began in a South Africa court on Tuesday to determine whether the government overpaid for Covid-19 vaccines, an allegation made by advocacy groups who contend that a lack of transparency may have masked pharmaceutical profits at the public’s expense. At issue are contracts signed by the South African government with several companies — including Johnson & Johnson and Pfizer — that provided millions of Covid-19 vaccines during the pandemic.

Vaccines 97

Vaccines 97

Fierce Pharma

JULY 25, 2023

To make Cabenuva the standard treatment option for HIV, Johnson & Johnson and GSK-owned ViiV Healthcare must first dethrone Gilead Sciences’ once-daily stalwart Biktarvy. | To make Cabenuva the standard treatment option for HIV, Johnson & Johnson and GSK-owned ViiV Healthcare must first dethrone Gilead Sciences’ once-daily stalwart Biktarvy.

98

98

Fierce Healthcare

JULY 25, 2023

Amid a worsening mental health crisis, the Biden administration is proposing a slew of regulatory changes aimed at improving access to critical care. | Amid a worsening mental health crisis, the Biden administration is proposing a slew of regulatory changes aimed at improving access to critical care.

98

98

European Pharmaceutical Review

JULY 25, 2023

Axatilimab, an anti-CSF-1R antibody to treat chronic graft-versus-host disease (GVHD) has, in a pivotal Phase II trial, demonstrated overall response rates (ORR) of 74 percent, 67 percent and 50 percent, within the first six months of treatment. “[It] is the first investigational chronic GVHD treatment to target inflammation and fibrosis through the inhibition of disease associated macrophages,” stated Michael A Metzger, Chief Executive Officer of Syndax Pharmaceuticals.

FDA 98

FDA 98

Fierce Healthcare

JULY 25, 2023

AHIP, the American Medical Association and the National Association of ACOs have teamed up to release a playbook that aims to arm stakeholders with best practices for value-based care. | Three major national organizations released a playbook to help payers and providers adapt to value-based care.

98

98

Pharma Marketing Network

JULY 25, 2023

Ads Manager is a powerful platform that can help pharma companies reach their target audience and achieve their marketing goals. One of the ways to do this is to customize your audience. This means targeting your ads to people who are most likely to be interested in your products or services. Here are some tips for customizing your audience in Ads Manager for the pharma industry: Use demographics: You can target your ads based on demographics, such as age, gender, location, and interests.

98

98

Fierce Healthcare

JULY 25, 2023

Community Health Systems (CHS) announced that it has signed a deal to sell three Florida hospitals to Tampa General Hospital for roughly $290 million. | The divestiture of Bravera Health Brooksville, Bravera Health Seven Rivers and Bravera Health Spring Hill is slated to close later this year pending regulatory approval and other customary closing conditions.

Hospitals 98

Hospitals 98

Fierce Pharma

JULY 25, 2023

Hopes around FibroGen’s anemia drug roxadustat were high in early 2020 when Enrique Conterno arrived as the company’s new CEO. | Enrique Conterno has resigned from the FibroGen CEO post for “personal reasons,” the company said Tuesday. As FibroGen looks for a permanent successor, the company’s chief commercial officier Thane Wettig will don the mantle of interim chief executive officer.

97

97

Fierce Healthcare

JULY 25, 2023

Editor's Note: The article has been updated with information from Teladoc's earnings call with investors late Tuesday afternoon. | Teladoc is doubling down on its strategy to focus on "whole person care" through its virtual care platform. The telehealth provider is seeing strong growth across its chronic care programs and virtual mental health and is eyeing opportunities in the booming weight management market.

98

98

STAT

JULY 25, 2023

Stoke Therapeutics is still seeking an effective dose for an experimental drug to treat a severe form of childhood epilepsy, following the release of updated data Tuesday that showed disappointing reductions in convulsive seizure activity. In the latest look at an ongoing mid-stage study, three monthly injections of the Stoke drug, called STK-001, given at a 45-mg dose, resulted in a median 18% reduction in convulsive seizure activity, compared to baseline.

93

93

Fierce Healthcare

JULY 25, 2023

Data breaches hurt all industries, but this is especially true for healthcare, which has lost the most financially to these incidents, according to a new report. | Healthcare seems particularly vulnerable to data breaches, and the problem’s gotten worse since COVID-19, according to a report published by IBM Security. The average cost of a data breach in healthcare grew 53.3% since 2020.

98

98

Pharmacy Times

JULY 25, 2023

Pharmacists should provide guidance on issues such as proper drug disposal and potential drug interactions.

120

120

Pharma Marketing Network

JULY 25, 2023

Google Ads is a great way to reach a wider audience for your pharma business. However, if you want to get the most out of your Google Ads campaigns, you need to optimize them for SEO. Here are some tips on how to increase SEO on Google Ads for the pharma industry: Use relevant keywords: When you’re creating your Google Ads campaigns, make sure to use relevant keywords.

97

97

Fierce Healthcare

JULY 25, 2023

King of Prussia, Pennsylvania-based Universal Health Services (UHS) reported a $171.3 million net gain ($2.42 per diluted share) for the second quarter of 2023, up slightly from the $164.1 million | The for-profit chain logged a 6.8% rise in net revenues over Q2 2022, with gains split across both of its acute and behavioral health businesses.

96

96